
(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
UN rights chief: Israel's new Gaza aid agency rules 'outrageous' - 2
Spain’s Picos de Europa: What to see and do in ‘the world’s most beautiful place’ - 3
Pick Your Favored kind of books - 4
Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how - 5
Polish law aimed at lowering petrol prices takes effect
From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
The EU Is Considering Lifting Tariffs on Chinese Electric Vehicles
UPM Adhesive Materials plans new facility near New Delhi, India
Mussolini's summer villa on Adriatic coast sold for €1.2 million
Without evidence, CDC changes messaging on vaccines and autism
The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
Pick Your Favored kind of salad













